Evidence map›Paper›PMID 39686528›Full record

ArticleInternational journal of cancer2025

Long-term risk and characteristics of cerebrovascular events after upper body radiotherapy among childhood cancer survivors in the DCCSS-LATER cohort.

Lisanne C Verbruggen, Judith L Kok, Leontien C M Kremer, Geert O Janssens, Paul J Nederkoorn, Adriaan Penson, A Birgitta Versluijs, Andrica C H de Vries, Ardine M J Reedijk, Dorine Bresters and 16 more

Abstract read
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.Current neurology and neuroscience reports · 2025
    Review
  2. Approaches to Reduce Toxicity in Pediatric Brain Tumors.Current oncology (Toronto, Ont.) · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Lisanne C VerbruggenPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Judith L KokPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Leontien C M KremerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Geert O JanssensPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Paul J NederkoornDepartment of Neurology, Amsterdam UMC, AMC, University of Amsterdam, Amsterdam, The Netherlands.
Adriaan PensonRadboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
A Birgitta VersluijsPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Andrica C H de VriesPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Ardine M J ReedijkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Dorine BrestersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Eelco W HovingPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Eline van Dulmen-den BroederDepartment of Pediatric Oncology/Hematology, Amsterdam UMC/VUmc, Amsterdam, The Netherlands.
Jacqueline J LoonenRadboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Judith de BontPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Joyce WilbersRadboudumc Center of Expertise for Cancer Survivorship, Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
Marloes LouwerensDepartment of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Margriet van der Heiden-van der LooPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Saskia M F PluijmPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Sebastian J C M M NeggersDepartment of Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands.
Wim J E TissingPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Yvo B W E M RoosDepartment of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Cécile M RonckersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Jop C TeepenPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-2647-2677
Helena J H van der PalPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
DCCSS‐LATER consortium

Funding

Children-Cancer Free Foundation 246
6 · The paper itself

Abstract

Cerebrovascular events (CVEs) are serious late adverse events among childhood cancer survivors. We estimated the incidence and risk factors of symptomatic CVEs and described the clinical characteristics among childhood cancer survivors after upper body radiotherapy. The Dutch Childhood Cancer Survivor Study LATER cohort study includes 5-year childhood cancer survivors diagnosed <age 18 years in the period 1963-2001. Data about CVEs were retrieved from medical records of survivors treated with upper body radiotherapy (n = 1633). Multivariable Cox and logistic regression models were used to identify potential risk factors for developing a symptomatic CVE. In 107 survivors with upper body radiotherapy, a CVE emerged, at a median age of 35.5 years. Cumulative incidence 40 years after diagnosis was 9.1% (95% CI: 7.2%-11.6%). A cranial radiotherapy prescription dose >50 Gy was associated with 6-fold increased risk, compared to upper body radiotherapy not involving the cranium (hazard ratio = 6.3, 95%CI: 3.3-12.1). In a subgroup with available data on lifestyle and comorbidities, hypertension (odds ratio[OR] = 6.2, 95%CI: 1.6-23.8) and obesity (BMI≥30 vs. <30 = 2.95, 95%CI: 1.1-8.0) significantly increased CVE risk. During CVE episode, 17 (16%) had a life-threatening situation, and two (2%) others died. In 28%, a second CVE developed during follow-up. At end of follow-up, 29% were deceased, and 40% of those alive were unable to carry out normal activities/active work. Childhood cancer survivors treated with higher doses of cranial radiotherapy are at highest risk for developing CVEs. CVEs occur at a young age and cause a high morbidity. Studies to investigate risk-reducing secondary preventive interventions are warranted.

Indexed as

Cancer SurvivorsCerebrovascular DisordersNeoplasmsRadiation InjuriesRadiotherapyAdolescentAdultChildChild, PreschoolCohort StudiesCranial IrradiationFemaleHumansIncidenceInfantMalecerebrovascular eventchildhood cancer survivorscranial radiotherapystroke

Identifiers

PMID39686528
PMCPMC11924307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.